Updated as of October 2026
For referrals, referring providers and potential participants can call/text 415-806-8554 or email ID-research.zsfg@ucsf.edu
Check out the division website for more information about these and other studies, including links to dowloadable IRB approved flyers by clicking on the study name/number: https://hividgm.ucsf.edu/open-clinical-trials
STUDIES FOR PEOPLE TAKING DOXY-PEP
- OBSERVATIONAL STUDY OF PEOPLE TAKING DOXYCYCLINE TO PREVENT SEXUALLY TRANSMITTED INFECTIONS (DOXYIMPACT): Observational study of men and women who are planning to start or who are already taking doxy-PEP/doxyPrEP. This study will look at real world effectiveness to reduce sexually transmitted infections and the potential impact of intermittent doxycycline use on antimicrobial resistance and on the microbiome. Participants may be living with or without HIV.
STUDIES FOR PEOPLE LIVING WITH HIV:
- COMING SOON: OPEN-LABEL RANDOMIZED CONTROLLED TRIAL OF WEEKLY ORAL INSTI+ORAL LENACAPAVIR VS. CONTINUED ORAL B/F/TAF (Gilead 8079): Phase II study evaluating two different doses of an investigational oral INSTI + oral lenacapavir given weekly compared to continued oral B/F/TAF. Inclusion criteria include virologically suppressed for ≥6 months, on B/F/TAF x ≥6 months, no known INSTI resistance, CD4 > 200 and HBsAg (-). Those randomized to SOC will have the option to take the investigational oral regimen after 48 weeks.
- OPEN-LABEL RANDOMIZED CONTROLLED TRIAL OF INTRAMUSCULAR GS-3242 (INSTI) + IM LENACAPAVIR VS. CONTINUED ORAL B/F/TAF (Gilead 7710): Phase II study evaluating two different doses of an investigational IM INSTI + IM LEN given every 4 months with a possible coming q 6 month arm, compared to continued oral B/F/TAF. Inclusion criteria include virologically suppressed for ≥6 months, on B/F/TAF x ≥6 months, no prior use of injectable HIV antivirals (intramuscular, subcutaneous or IV routes), HBsAg (-) and no prior virologic failure on an INSTI based regimen. Those randomized to SOC will have the option to take the injectable regimen after 52 weeks.
- OPEN-LABEL RANDOMIZED CONTROLLED TRIAL OF SUBCUTANEOUS LENACAPAVIR WITH TWO IV MONOCLONAL ANTIBODIES VS. CONTINUED ORAL ART (Gilead 6544): Phase III study evaluating SQ LEN + 2 monoclonal antibodies (teropavimab + zinlirvimab) given every 6 months vs continued current oral ART, with a 1:1 randomization. Inclusion criteria include virologically suppressed for ≥ 6 months, no prior use of injectable HIV antivirals (intramuscular, subcutaneous or IV routes), HBsAg (-) and no prior virologic failure on an INSTI based regimen. Potential candidates will be screened for susceptibility to the two monoclonal antibodies as part of the study. Those randomized to continued standard care ART will have the option to take the injectable regimen after 2 years.
- MENOPAUSAL HORMONE THERAPY FOR WOMEN LIVING WITH HIV (ACTG 5242) Phase 4, randomized, double-blind, placebo-controlled, parallel trial of hormone therapy with transdermal estradiol (with or without oral progesterone, depending on intact uterus status) versus placebo for women living with HIV in the late menopausal transition or early post menopause with moderate or severe vasomotor symptoms. Cis-gender women ages 40-60, on ART for ≥ 48 weeks, will be randomized to hormone replacement therapy (HRT) vs blinded placebo for 12 weeks to evaluate HRT impact on vasomotor symptoms.
- ALENDRONATE IMPACT ON THE HIV RESERVOIR (ACTG 5428): This randomized placebo-controlled trial evaluates alendronate, an osteoporosis treatment that also is under investigation for potential HIV latency reversing properties. Participants will be randomized 2:1 to receive weekly oral alendronate vs placebo for 24 weeks with a primary endpoint of change in the HIV reservoir. Eligibility criteria include well-controlled HIV on ART ≤ 10 years , ≤65 years old and no known osteoporosis.
- STUDY OF CHOLESTEROL LOWERING MEDICAITON IN PWH WITH KNOWN CVD OR RISK FACTORS (CLEAR-HIV Study) Double blinded, randomized trial evaluating at Bempedoic acid 180 mg taken orally once daily for one year compared to placebo in participants with HIV and heart disease or risk of heart disease. Additionally, the study is looking at whether Bempedoic acid compared to placebo improves vascular inflammation and plaque buildup in the arteries. Statin use is allowed (no start/stop of statin, or dose changes while on study). Contact 415 353-4347 or alexxis.levya@ucsf.
STUDIES FOR PEOPLE TAKING HIV PREP
- no current studies
STUDIES OF COVID VACCINATION
- no current studies
STUDIES FOR PEOPLE WITH HCV
- STUDY OF PHARMACOKINETICS OF HCV TREATMENT DURING PREGNANCY (IMPAACT 2041). Phase I/II single arm, open label study of 8 weeks of oral glecaprevir/pibrenstasvir (G/P) to initiate HCV treatment during the 2nd trimester of pregnancy. Intensive PK will be conducted at week 3 and week 6 after treatment initiation. G/P will be provided by the study